91 related articles for article (PubMed ID: 241485)
21. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation.
Mani C; Hodgson E; Kupfer D
Drug Metab Dispos; 1993; 21(4):657-61. PubMed ID: 8104125
[TBL] [Abstract][Full Text] [Related]
23. An unexpected pathway for the metabolic degradation of 1,3-dialkyl-3-acyltriazenes.
Rouzer CA; Thompson EJ; Skinner TL; Heavner PA; Bartolini WP; Mitchell K; Kurz E; Smith RH; Michejda CJ
Biochem Pharmacol; 1993 Jul; 46(1):165-73. PubMed ID: 8347127
[TBL] [Abstract][Full Text] [Related]
24. The metabolism of triazene antitumor drugs.
Gescher A; Threadgill MD
Pharmacol Ther; 1987; 32(2):191-205. PubMed ID: 3299401
[No Abstract] [Full Text] [Related]
25. Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterization and effects of reactive oxygen scavengers.
Mimnaugh EG; Gram TE; Trush MA
J Pharmacol Exp Ther; 1983 Sep; 226(3):806-16. PubMed ID: 6411900
[TBL] [Abstract][Full Text] [Related]
26. Characterization and modulation by drugs of sheep liver microsomal flavin monooxygenase activity.
Can Demirdöğen B; Adali O
Cell Biochem Funct; 2005; 23(4):245-51. PubMed ID: 15473006
[TBL] [Abstract][Full Text] [Related]
27. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
Carter SK; Friedman MA
Eur J Cancer (1965); 1972 Feb; 8(1):85-92. PubMed ID: 4552317
[No Abstract] [Full Text] [Related]
28. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
[TBL] [Abstract][Full Text] [Related]
29. Inhibition and induction of rabbit liver microsomal cytochrome P-450 by pyridine.
Kaul KL; Novak RF
J Pharmacol Exp Ther; 1987 Oct; 243(1):384-90. PubMed ID: 3668864
[TBL] [Abstract][Full Text] [Related]
30. Enzyme catalyzation of the deacylation of N4-acyl derivatives of 1-beta-D-arabinofuranosylcytosine in the mouse liver microsome.
Tsuruo T; Hori K; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1982 Jun; 42(6):2250-4. PubMed ID: 7074607
[TBL] [Abstract][Full Text] [Related]
31. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
Nicolin A; Franco P; Testorelli C; Goldin A
Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
[TBL] [Abstract][Full Text] [Related]
32. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.
Hill DL; Laster WR; Kirk MC; el-Dareer S; Struck RF
Cancer Res; 1973 May; 33(5):1016-22. PubMed ID: 4703116
[No Abstract] [Full Text] [Related]
34. Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s.
Tang C; Chiba M; Nishime J; Hochman JH; Chen I; Williams TM; Lin JH
Drug Metab Dispos; 2000 Jun; 28(6):680-6. PubMed ID: 10820141
[TBL] [Abstract][Full Text] [Related]
35. Oxidation of ethylene glycol to formaldehyde by rat liver microsomes. Role of cytochrome P-450 and reactive oxygen species.
Kukiełka E; Cederbaum AI
Drug Metab Dispos; 1991; 19(6):1108-15. PubMed ID: 1687018
[TBL] [Abstract][Full Text] [Related]
36. Stochastic compartmental modeling of the disposition of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
McInnis B; Kapadia A; El-Asfouri S; Loo TL
Cancer Chemother Rep; 1975; 59(4):843-5. PubMed ID: 1175174
[No Abstract] [Full Text] [Related]
37. Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.
Breithaupt H; Dammann A; Aigner K
Cancer Chemother Pharmacol; 1982; 9(2):103-9. PubMed ID: 7172404
[TBL] [Abstract][Full Text] [Related]
38. Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors.
Levin VA; Crafts D; Wilson CB; Kabra P; Hansch C; Boldrey E; Enot J; Neely M
Cancer Chemother Rep; 1975; 59(2 Pt 1):327-31. PubMed ID: 1149010
[No Abstract] [Full Text] [Related]
39. Synthesis of 5-(3, 3-disubstituted-1-triazenyl) imidazole-4-carbonitriles.
Shealy YF; O'Dell CA
J Pharm Sci; 1975 Jun; 64(6):954-6. PubMed ID: 1133749
[TBL] [Abstract][Full Text] [Related]
40. Microsomal mediated metabolism of dialkylaryltriazenes. II. Isolation and identification of metabolites of 3,3-dimethyl-1-phenyltriazene.
Pool BL
J Cancer Res Clin Oncol; 1979 Apr; 93(3):221-31. PubMed ID: 468885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
